Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00818389 · ClinicalTrials.gov registry record · Phase 2
Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT00818389: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT00818389 is a Phase 2 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 84 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00818389, a Phase 2 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effectiveness of lithium combined with riluzole to riluzole combined with placebo in people with amyotrophic lateral sclerosis.
Interventions
- DRUG placebo
- DRUG Riluzole
- DRUG Lithium Carbonate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00818389
The ClinicalTrials.gov registry entry for NCT00818389 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00818389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00818389 about?
NCT00818389 is a clinical study titled "Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)". The purpose of this study is to compare the effectiveness of lithium combined with riluzole to riluzole combined with placebo in people with amyotrophic lateral sclerosis.
What is the current status of trial NCT00818389?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2009-01. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00818389?
The interventions under investigation include: placebo (DRUG), Riluzole (DRUG), Lithium Carbonate (DRUG).
Who is sponsoring clinical trial NCT00818389?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.